- Home
- COGT vs MGIC Comparison
COGT vs MGIC Comparison
Compare COGT & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- MGIC
- Stock Information
- Founded
- COGT 2014
- MGIC 1983
- Country
- COGT United States
- MGIC Israel
- Employees
- COGT N/A
- MGIC N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- MGIC Computer Software: Prepackaged Software
- Sector
- COGT Health Care
- MGIC Technology
- Exchange
- COGT Nasdaq
- MGIC Nasdaq
- Market Cap
- COGT 806.1M
- MGIC 788.0M
- IPO Year
- COGT 2018
- MGIC 1991
- Fundamental
- Price
- COGT $7.41
- MGIC $20.33
- Analyst Decision
- COGT Buy
- MGIC Buy
- Analyst Count
- COGT 6
- MGIC 2
- Target Price
- COGT $15.20
- MGIC $16.00
- AVG Volume (30 Days)
- COGT 2.4M
- MGIC 63.9K
- Earning Date
- COGT 08-05-2025
- MGIC 08-13-2025
- Dividend Yield
- COGT N/A
- MGIC 2.81%
- EPS Growth
- COGT N/A
- MGIC 1.33
- EPS
- COGT N/A
- MGIC 0.76
- Revenue
- COGT N/A
- MGIC $569,136,000.00
- Revenue This Year
- COGT N/A
- MGIC $7.53
- Revenue Next Year
- COGT N/A
- MGIC $8.96
- P/E Ratio
- COGT N/A
- MGIC $25.88
- Revenue Growth
- COGT N/A
- MGIC 6.37
- 52 Week Low
- COGT $3.72
- MGIC $9.64
- 52 Week High
- COGT $12.61
- MGIC $20.44
- Technical
- Relative Strength Index (RSI)
- COGT 64.24
- MGIC 84.55
- Support Level
- COGT $7.07
- MGIC $17.93
- Resistance Level
- COGT $7.50
- MGIC $18.26
- Average True Range (ATR)
- COGT 0.43
- MGIC 0.43
- MACD
- COGT -0.06
- MGIC 0.30
- Stochastic Oscillator
- COGT 55.94
- MGIC 97.97
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.